Cognito Therapeutics Company Profile 2024: Valuation, Funding ...

Cognito Therapeutics General Information Description. Developer of disease-modifying digital therapeutics designed to cure neurodegenerative disorders. The company's therapies use …

CouponFollow Extension

$118.25
OFF

Cognito Therapeutics Stock Price, Funding, Valuation, Revenue ...

1 week from now

Jul 2, 2024 · Funding, Valuation & Revenue. 5 Fundings. Cognito Therapeutics has raised $118.25M over 5 rounds.. Cognito Therapeutics's latest funding round was a Series B - III for …

cbinsights.com

$227
OFF

Cognito Therapeutics - Raised $227M Funding From 6 Investors

1 week from now

Oct 29, 2024 · Cognito Therapeutics has raised a total funding of $227M over 5 rounds from 6 investors. Investors include Morningside, FoundersX Ventures and 4 others. Their latest …

tracxn.com

$35000000
OFF

Series B - Cognito Therapeutics - 2024-01-29 - Crunchbase

1 week from now

Jan 29, 2024 · Cognito Therapeutics raised $35000000 on 2024-01-29 in Series B. Search Crunchbase. Start Free Trial . Chrome Extension ... Summary. Overview. Edit Overview …

crunchbase.com

$35
OFF

Cognito Nets $35 Million To Advance Alzheimer's DTx Trial

1 week from now

Jan 29, 2024 · Cognito Therapeutics has raised $35 million to advance its digital therapeutic (DTx) for Alzheimer's disease, the company's CEO Brent Vaughan told FirstWord HealthTech …

firstwordhealthtech.com

$73
OFF

Cognito | Company Overview & News - Forbes

1 week from now

Cognito Therapeutics, an MIT-based neurotechnology company, made headlines this year when they announced a $73 million investment into a premier therapy for Alzheimer’s.

forbes.com

$9
OFF

Cognition Therapeutics Reports Financial Results For The Third …

1 week from now

5 days ago · The Company reported a net loss of $9.9 million, or $(0.25) per basic and diluted share for the third quarter ended September 30, 2024, compared to a net loss of $6.7 million, …

businessinsider.com

$0.01
OFF

Serina Therapeutics Reports Third Quarter 2024 Financial Results …

1 week from now

6 days ago · Redeemable convertible preferred stock, $0.01 par value; 10,000 authorized; none and 3,438 issued and outstanding at September 30, 2024 and December 31, 2023, …

morningstar.com

$30
OFF

Omega Therapeutics Announces Successful Completion Of Phase 1 …

1 week from now

4 days ago · Third Quarter 2024 Financial Results. As of September 30, 2024, the Company had cash and cash equivalents totaling $30.4 million, which is expected to fund operations into Q2 …

omegatherapeutics.com

FAQs about Cognito Therapeutics Company Profile 2024: Valuation, Funding ... Coupon?

What did cognition Therapeutics (CGTX) do in the third quarter 2024?

PURCHASE, N.Y., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”) today reported financial results for the third quarter ended September 30, 2024, and provided a business update. ...

Who is the CEO of cognito health?

Mark Hostak is the CEO of Cognito Health. Where is Cognito Health headquartered? Cognito Health is headquartered in Goodyear, AZ. What industry is Cognito Health in? Cognito Health’s primary industry is Enterprise Systems (Healthcare). Is Cognito Health a private or public company? Cognito Health is a Private company. ...

What did cognition Therapeutics achieve in the third quarter?

“In the third quarter and recent weeks Cognition Therapeutics achieved one of the most important milestones in its history as the Phase 2 SHINE study results became available. ...